Stage IV Uveal Melanoma AJCC v7 Clinical Trial
Official title:
A Randomized Two-Arm Phase II Study of Trametinib Alone and in Combination With GSK2141795 in Patients With Advanced Uveal Melanoma
This randomized phase II trial studies how well trametinib with or without Akt inhibitor GSK2141795 (GSK2141795) works in treating patients with uveal melanoma that has spread to other parts of the body (metastatic). Trametinib and GSK2141795 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether trametinib is more effective with or without GSK2141795 in treating patients with metastatic uveal melanoma.
PRIMARY OBJECTIVES:
I. To compare progression-free survival between those treated with trametinib alone and those
treated with the combination of trametinib and GSK2141795.
SECONDARY OBJECTIVES:
I. To compare overall survival between those treated with trametinib alone and those treated
with the combination of trametinib and GSK2141795.
II. To compare the overall response rate between those treated with trametinib alone and
those treated with the combination of trametinib and GSK2141795.
III. To compare the safety and toxicity between those treated with trametinib alone and those
treated with the combination of trametinib and GSK2141795.
TERTIARY OBJECTIVES:
I. To assess clinical outcomes (response rate, progression-free and overall survival) with
trametinib and GSK2141795 after progression on trametinib.
II. To assess toxicity with trametinib and GSK2141795 after progression on trametinib.
III. To correlate clinical outcome with Gnaq/11 mutational status. IV. To assess the
pharmacodynamic effects of trametinib alone and with GSK2141795, and utilize
whole-transcriptome and reverse phase protein array to identify markers of sensitivity and
primary resistance to trametinib alone and with GSK2141795.
V. To assess for changes in circulating tumor deoxyribonucleic acid (DNA) with therapy.
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
ARM A: Patients receive trametinib orally (PO) once daily (QD) on days 1-28. Courses repeat
every 4 weeks in the absence of disease progression or unacceptable toxicity. Patients who
experience objective disease progression may crossover to Arm B. (no patients will be
enrolled to Arm B or Crossover therapy as of 11/6/2015)
ARM B: Patients receive trametinib PO QD and Akt inhibitor GSK2141795 PO QD on days 1-28.
Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up for 4 weeks and then every 12
weeks thereafter.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02363283 -
Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma
|
Phase 2 | |
Completed |
NCT02158520 -
Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery
|
Phase 2 | |
Completed |
NCT01585194 -
Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma
|
Phase 2 | |
Active, not recruiting |
NCT01587352 -
Vorinostat in Treating Patients With Metastatic Melanoma of the Eye
|
Phase 2 | |
Active, not recruiting |
NCT03472586 -
Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver
|
Phase 2 | |
Completed |
NCT01835145 -
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
|
Phase 2 | |
Completed |
NCT01989572 -
Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery
|
Phase 3 | |
Completed |
NCT02519322 -
Neoadjuvant and Adjuvant Checkpoint Blockade
|
Phase 2 | |
Withdrawn |
NCT03326258 -
Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery
|
Phase 1/Phase 2 |